It will be possible to start production of the Russian Sputnik V vaccine against COVID-19 in Brazil no earlier than the second half of 2021. This was announced on Wednesday, August 12, by Reuters, citing the head of the Institute of Technology of the State of Parana (Tecpar) Jorge Callao.
According to him, such a timing for the start of production of the drug is due to a conservative and cautious approach.
“Of course, this does not mean that the government cannot import it directly, it is possible even before production starts. It can be imported earlier if it is certified and registered in Brazil, ”Callao said.
Testing of the Russian drug in Brazil will take place at the Institute of Technology of the State of Parana (Tecpar), and if, as a result, the institute becomes interested in the production of a vaccine, then this will require an investment of 80 million reais (about $ 15 million) at the expense of foreign investors or federal authorities, the agency notes. …
Earlier on Wednesday, the Russian Direct Investment Fund (RDIF) and the Brazilian state of Parana agreed to jointly promote Sputnik V. Within the framework of the signed agreement, the production of the Russian vaccine and its delivery to Brazil and other countries of Latin America will be organized. In the near future, RDIF and Research Center for Epidemiology and Microbiology. NF Gamalei are ready to provide Tecpar with the results of clinical trials of the vaccine and technological protocols for its production.
On Wednesday, the head of RDIF Kirill Dmitriev and the governor of the Brazilian state of Parana Ratiño Junior signed a memorandum of understanding, on the basis of which it is planned to test a Russian vaccine against coronavirus in this southern region of Brazil with the subsequent possibility of its production. The ceremony was held in the format of a video conference.
On August 11, Russian President Vladimir Putin announced the registration of the first coronavirus vaccine in Russia. The drug was developed by the Center. N. Gamalei.
The first recipients of the vaccine from the Gamaleya Center will be health workers and the elderly. The effectiveness of the drug will be assessed based on the results of the formation of population immunity.